Medigene to Participate in Five Investment and Scientific Conferences in November

Medigene AG / Medigene to Participate in Five Investment and Scientific Conferences in November . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Press Release

  

Martinsried/Munich, 3 November, 2014. Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in five international conferences:

BIO-Europe - Annual International Partnering Conference

Date: 3 - 5 November 2014
Location: Frankfurt am Main, Germany

The Society for Immunotherapy of Cancer (SITC)

Date: 7 - 9 November 2014
Location: National Harbor (Washington D.C.), USA
Poster Presentation on 8 November focusing the TCR immunotherapy platform titled "Generation of tumor antigen-specific CD4+ and CD8+ T cells by simultaneous MHC-I and -II epitope presentation in vitro and in vivo"

Jefferies Global Healthcare Conference

Date: 19 - 20 November 2014
Location: London, Great Britain

German Equity Forum

Date: 24 - 26 November 2014
Location: Frankfurt am Main, Germany
Company Presentation at 25 November 5 pm

BayImmuNet - International Symposium on Interventional Immunology from Cells to Drugs

Date: 13 - 14 November 2014
Location: Regensburg, Germany
Chair: Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please visit: http://www.medigene.de/unsubscribe

Press release as PDF


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire
HUG#1867724

--- End of Message ---

Medigene AG
Lochhamer Strasse 11 Martinsried / München Germany

WKN: A1X3W0;ISIN: DE000A1X3W00;
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;